CLINICAL TRIALS PROFILE FOR EDIVOXETINE
✉ Email this page to a colleague
Clinical Trials for Edivoxetine
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT00420004 ↗ | A Study for Participants With Major Depression | Completed | Eli Lilly and Company | Phase 2 | This is a study to assess the safety and effectiveness of LY2216684 compared to placebo in treating adults with major depressive disorder. |
NCT00922636 ↗ | A Study of Pediatric Patients With Attention Deficit/Hyperactivity Disorder | Completed | Eli Lilly and Company | Phase 2/Phase 3 | The primary purpose of your child's participation in this study is to determine whether LY2216684 can help pediatric patients with attention-deficit/hyperactivity disorder (ADHD); and assess the safety of LY2216684 and any side effects that might be associated with it. |
NCT00965419 ↗ | A Study of Pediatric Participants With Attention Deficit/Hyperactivity Disorder | Terminated | Eli Lilly and Company | Phase 2/Phase 3 | The primary purpose of the study is to assess long-term safety and tolerability of Edivoxetine in pediatric participants with attention deficit hyperactive disorder (ADHD). |
NCT01155661 ↗ | A Safety Study in Participants With Major Depressive Disorder | Completed | Eli Lilly and Company | Phase 3 | The primary objective of this study is to evaluate the long-term safety and tolerability of LY2216684 administered once daily (QD) in the adjunctive treatment with a selective serotonin reuptake inhibitor (SSRI) for up to approximately 1 year in participants with major depressive disorder (MDD) who are partial responders to their SSRI treatment. |
NCT01173601 ↗ | A Fixed Dose Study of Adjunctive Treatment to Antidepressant Therapy for Adults With Major Depressive Disorder | Completed | Eli Lilly and Company | Phase 3 | The primary purpose of this study is to assess whether at least 1 dose of LY2216684 (12 milligrams [mg] or 18 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder (MDD) who were identified as partial responders to an adequate course of treatment with a selective serotonin reuptake inhibitor (SSRI) during an 8-week, double-blind, acute adjunctive treatment phase. |
NCT01185340 ↗ | A Study in Participants With Major Depressive Disorder Who Are Partial Responders to Selective Serotonin Reuptake Inhibitor | Completed | Eli Lilly and Company | Phase 3 | The primary objective of this study is to assess whether LY2216684 12 milligrams (mg) or 18 mg flexible dose once daily is superior to placebo once daily in the adjunctive treatment of participants with major depressive disorder (MDD) who are partial responders to their selective serotonin reuptake inhibitor (SSRI) treatment. |
NCT01187407 ↗ | A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment | Completed | Eli Lilly and Company | Phase 3 | The purpose of this study is to assess if LY2216684 (flexible dose of 12 to 18 milligrams [mg] or fixed dose of 6 mg once daily) is superior to placebo once daily in the adjunctive treatment of participants with Major Depressive Disorder (MDD) who were identified as partial responders to an adequate course of treatment with a selective serotonin reuptake inhibitor (SSRI) during an 8-week, double-blind, acute adjunctive treatment phase. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for Edivoxetine
Condition Name
Clinical Trial Locations for Edivoxetine
Trials by Country
Clinical Trial Progress for Edivoxetine
Clinical Trial Phase
Clinical Trial Sponsors for Edivoxetine
Sponsor Name